Whan In Pharm Co.,Ltd. (KRX:016580)
South Korea
· Delayed Price · Currency is KRW 11,410
-90 (-0.78%)
Last updated: Mar 28, 2025
Whan In Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Other Revenue | - | - | -0 | -0 | 0 | Upgrade
|
| Revenue | 259,596 | 230,394 | 198,935 | 177,776 | 171,705 | Upgrade
|
| Revenue Growth (YoY) | 12.68% | 15.81% | 11.90% | 3.54% | 7.87% | Upgrade
|
| Cost of Revenue | 165,931 | 131,451 | 100,277 | 84,416 | 85,204 | Upgrade
|
| Gross Profit | 93,665 | 98,943 | 98,658 | 93,359 | 86,501 | Upgrade
|
| Selling, General & Admin | 67,564 | 64,470 | 61,948 | 55,849 | 51,936 | Upgrade
|
| Research & Development | 771.13 | 1,072 | 3,331 | 2,659 | 3,312 | Upgrade
|
| Other Operating Expenses | 1,300 | 1,311 | 1,273 | 1,238 | 1,093 | Upgrade
|
| Operating Expenses | 72,170 | 68,772 | 68,847 | 62,083 | 58,083 | Upgrade
|
| Operating Income | 21,495 | 30,170 | 29,810 | 31,276 | 28,418 | Upgrade
|
| Interest Expense | -23.12 | -22.66 | -51.88 | -51.55 | -31.42 | Upgrade
|
| Interest & Investment Income | 2,971 | 3,769 | 2,500 | 1,821 | 1,676 | Upgrade
|
| Earnings From Equity Investments | 1,981 | -1,006 | -201.08 | -61.86 | -31.74 | Upgrade
|
| Currency Exchange Gain (Loss) | -69.24 | -141.12 | 343.44 | 223.56 | -201.3 | Upgrade
|
| Other Non Operating Income (Expenses) | 528.81 | 1,016 | 153.71 | 329.1 | 66.98 | Upgrade
|
| EBT Excluding Unusual Items | 26,884 | 33,785 | 32,555 | 33,536 | 29,897 | Upgrade
|
| Gain (Loss) on Sale of Investments | 392.98 | 1,895 | 925.83 | 794.08 | 1,299 | Upgrade
|
| Gain (Loss) on Sale of Assets | -330.11 | -1,160 | -1,897 | -6.22 | -63.52 | Upgrade
|
| Asset Writedown | - | -726.43 | -1,776 | -442.01 | -50.27 | Upgrade
|
| Pretax Income | 26,947 | 33,793 | 29,808 | 33,882 | 31,082 | Upgrade
|
| Income Tax Expense | 3,566 | 4,019 | 6,075 | 7,423 | 7,890 | Upgrade
|
| Earnings From Continuing Operations | 23,381 | 29,774 | 23,734 | 26,459 | 23,191 | Upgrade
|
| Minority Interest in Earnings | - | - | 187.76 | 201.09 | 196.49 | Upgrade
|
| Net Income | 23,381 | 29,774 | 23,921 | 26,660 | 23,388 | Upgrade
|
| Net Income to Common | 23,381 | 29,774 | 23,921 | 26,660 | 23,388 | Upgrade
|
| Net Income Growth | -21.47% | 24.47% | -10.27% | 13.99% | 25.09% | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| EPS (Basic) | 1531.45 | 1950.23 | 1566.86 | 1746.22 | 1531.91 | Upgrade
|
| EPS (Diluted) | 1531.45 | 1950.23 | 1566.86 | 1746.00 | 1531.91 | Upgrade
|
| EPS Growth | -21.47% | 24.47% | -10.26% | 13.98% | 25.09% | Upgrade
|
| Free Cash Flow | -6,664 | -7,334 | -16,799 | 30,931 | 14,767 | Upgrade
|
| Free Cash Flow Per Share | -436.48 | -480.39 | -1100.32 | 2025.98 | 967.21 | Upgrade
|
| Dividend Per Share | - | 300.000 | 300.000 | 300.000 | 300.000 | Upgrade
|
| Gross Margin | 36.08% | 42.95% | 49.59% | 52.52% | 50.38% | Upgrade
|
| Operating Margin | 8.28% | 13.10% | 14.99% | 17.59% | 16.55% | Upgrade
|
| Profit Margin | 9.01% | 12.92% | 12.03% | 15.00% | 13.62% | Upgrade
|
| Free Cash Flow Margin | -2.57% | -3.18% | -8.44% | 17.40% | 8.60% | Upgrade
|
| EBITDA | 29,970 | 36,830 | 34,657 | 35,478 | 32,488 | Upgrade
|
| EBITDA Margin | 11.54% | 15.99% | 17.42% | 19.96% | 18.92% | Upgrade
|
| D&A For EBITDA | 8,475 | 6,659 | 4,847 | 4,202 | 4,070 | Upgrade
|
| EBIT | 21,495 | 30,170 | 29,810 | 31,276 | 28,418 | Upgrade
|
| EBIT Margin | 8.28% | 13.10% | 14.99% | 17.59% | 16.55% | Upgrade
|
| Effective Tax Rate | 13.23% | 11.89% | 20.38% | 21.91% | 25.39% | Upgrade
|
| Advertising Expenses | 15,285 | 12,359 | 10,387 | 9,519 | 7,069 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.